Page last updated: 2024-10-20

pyridoxamine and Obesity

pyridoxamine has been researched along with Obesity in 7 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" Previously, we reported the possible effect of pyridoxamine (K-163), an AGE inhibitor, on improvement of glucose intolerance in type 2 diabetes mellitus KK-A(y)/Ta mice."7.75Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. ( Funabiki, K; Gohda, T; Hagiwara, S; Horikoshi, S; Ito, T; Matsumoto, M; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Yamazaki, T, 2009)
"Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications."5.43Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016)
"The advanced glycation end product inhibitor pyridoxamine (PYR) and the antioxidant alpha-lipoic acid (LA) interact to ameliorate insulin resistance in obese Zucker rats following short-term (6-week) treatment."3.75Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats. ( Diehl, CJ; Hasselwander, O; Henriksen, EJ; Lindborg, KA; Matuschek, M; Muellenbach, EM; Teachey, MK, 2009)
" Previously, we reported the possible effect of pyridoxamine (K-163), an AGE inhibitor, on improvement of glucose intolerance in type 2 diabetes mellitus KK-A(y)/Ta mice."3.75Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. ( Funabiki, K; Gohda, T; Hagiwara, S; Horikoshi, S; Ito, T; Matsumoto, M; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Yamazaki, T, 2009)
"Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications."1.43Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Van den Eynde, MDG1
Houben, AJHM1
Scheijen, JLJM1
Linkens, AMA1
Niessen, PM2
Simons, N1
Hanssen, NMJ1
Kusters, YHAM1
Eussen, SJMP1
Miyata, T2
Stehouwer, CDA1
Schalkwijk, CG3
Ibrahim, GR1
Shah, I1
Gariballa, S1
Yasin, J1
Barker, J1
Salman Ashraf, S1
Maessen, DE1
Brouwers, O1
Gaens, KH2
Wouters, K1
Cleutjens, JP1
Janssen, BJ1
Stehouwer, CD2
Muellenbach, EM1
Diehl, CJ1
Teachey, MK1
Lindborg, KA1
Hasselwander, O1
Matuschek, M1
Henriksen, EJ1
Hagiwara, S1
Gohda, T1
Tanimoto, M1
Ito, T1
Murakoshi, M1
Ohara, I1
Yamazaki, T1
Matsumoto, M1
Horikoshi, S1
Funabiki, K1
Tomino, Y1
Unoki-Kubota, H1
Yamagishi, S1
Takeuchi, M1
Bujo, H1
Saito, Y1
Rensen, SS1
Buurman, WA1
Greve, JW1
Driessen, A1
Wolfs, MG1
Hofker, MH1
Bloemen, JG1
Dejong, CH1

Trials

1 trial available for pyridoxamine and Obesity

ArticleYear
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:5

    Topics: Female; Glycation End Products, Advanced; Humans; Insulin Resistance; Magnesium Oxide; Maillard Reac

2023

Other Studies

6 other studies available for pyridoxamine and Obesity

ArticleYear
Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.
    Molecules (Basel, Switzerland), 2020, Aug-28, Volume: 25, Issue:17

    Topics: Adolescent; Adult; Biomarkers; Chromatography, Liquid; Cross-Sectional Studies; Female; Humans; Male

2020
Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice.
    Diabetes, 2016, Volume: 65, Issue:4

    Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Arrhythmias, Cardiac; Cells, Cultured; Diet, High-Fat; Drug A

2016
Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats.
    Life sciences, 2009, Apr-10, Volume: 84, Issue:15-16

    Topics: Animals; Antioxidants; Blood Glucose; Drug Synergism; Female; Glucose Tolerance Test; Glycation End

2009
Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:7

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Adipokines; Adipose Tissue; Animals; Antioxidants; Cholesterol; Deoxygu

2009
Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice.
    Protein and peptide letters, 2010, Volume: 17, Issue:9

    Topics: Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Insulin Resistance; Male; Mice

2010
Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
    Journal of hepatology, 2012, Volume: 56, Issue:3

    Topics: Aged; Biomarkers; Biopsy; Cytokines; Enzyme Inhibitors; Fatty Liver; Female; Gene Expression; Guanid

2012